List of Excipients in Branded Drug INDIUM DTPA IN 111

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medi-Physics Inc dba GE Healthcare	INDIUM DTPA IN 111	indium in-111 pentetate disodium	17156-251	PENTETIC ACID
Medi-Physics Inc dba GE Healthcare	INDIUM DTPA IN 111	indium in-111 pentetate disodium	17156-251	SODIUM BICARBONATE

# Indium In-111 DTPA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Indium In-111 DTPA is a sterile diagnostic radiopharmaceutical in which diethylenetriaminepentaacetic acid, or DTPA, chelates indium-111 for imaging applications, including cerebrospinal-fluid flow and shunt evaluation. Its commercial opportunity is limited by a narrow clinical market, a 67.3-hour radionuclide half-life, specialized handling requirements, and competition from technetium-99m and newer PET-based diagnostics. The strongest product strategy is a low-excipient, preservative-free, single-dose formulation optimized for radiochemical stability, intrathecal tolerability, sterility, and regional distribution.

What is Indium In-111 DTPA used for?

Indium In-111 DTPA is a radiolabeled DTPA complex used primarily for diagnostic nuclear medicine procedures involving cerebrospinal-fluid circulation. The route of administration and clinical indication determine the formulation and manufacturing controls.

Attribute	Indium In-111 DTPA
Active radiolabeled complex	Indium-111 diethylenetriaminepentaacetic acid
Radionuclide	Indium-111
Physical half-life	Approximately 67.3 hours
Imaging modality	SPECT or planar nuclear imaging
Primary clinical use	Cisternography and cerebrospinal-fluid flow or shunt evaluation
Administration	Typically intrathecal for CSF studies
Product type	Sterile diagnostic radiopharmaceutical
Biosimilar pathway	Not applicable
Main competitors	Technetium-99m DTPA, CT or MRI-based evaluation, PET tracers in selected indications
Main commercial constraint	Short radioactive shelf life and specialized distribution

The DTPA ligand is central to product performance. It binds indium-111 and limits release of free indium, which can alter biodistribution and increase radiation exposure to non-target tissues. DTPA should therefore be treated as a functional chelating component rather than an inert excipient.

What excipients are appropriate for Indium In-111 DTPA?

The preferred formulation is a simple aqueous solution containing the indium-111-DTPA complex, water for injection, sodium chloride or another isotonicity adjustment, and pH-adjusting agents. The final composition should be consistent with the approved reference product and the intended route of administration.

Formulation function	Preferred approach	Commercial rationale
Chelation	Controlled DTPA concentration and stoichiometric excess where supported by the reference product	Reduces free indium and supports radiochemical purity
Vehicle	Water for injection	Minimizes component complexity
Tonicity	Sodium chloride or validated isotonicity adjustment	Important for intrathecal tolerability
pH control	Hydrochloric acid and sodium hydroxide, or equivalent validated agents	Maintains chelate stability and physiological compatibility
Preservation	Preservative-free, single-dose presentation	Preferred for intrathecal administration
Antioxidant system	Avoid unless justified by stability data	Limits added toxicity and regulatory complexity
Surfactant	Generally unnecessary	Reduces particulate, adsorption, and route-specific safety concerns
Buffer	Low-capacity buffer only if required	Strong buffers can affect complexation and intrathecal tolerability
Container	Low-sorption glass vial or validated polymer system	Supports dose recovery and radiochemical stability

A commercial developer should avoid unnecessary excipients. Surfactants, antimicrobial preservatives, high-concentration buffers, and unneeded antioxidants provide limited value in a short-lived, single-dose intrathecal radiopharmaceutical.

How should the excipient strategy address radiochemical stability?

Radiochemical stability is the principal technical objective. Indium-111 DTPA must maintain complex integrity through release, transport, dose preparation, and administration.

Key controls include:

1. DTPA concentration and metal-to-ligand ratio.
2. Radiochemical purity at release and at the end of the labeled shelf life.
3. Control of competing metals, including iron, zinc, copper, calcium, and trace metals from equipment or containers.
4. Control of pH and ionic strength.
5. Protection against radiolysis during storage.
6. Control of visible and subvisible particulate matter.
7. Validation of dose recovery from the vial and syringe.

Radiolysis can produce degradation products during storage, particularly at high radioactive concentrations. Developers should assess whether headspace control, shielding, concentration limits, or a low-level antioxidant system improves stability without affecting intrathecal safety. Any antioxidant must be justified by toxicology, compatibility, and radiochemical data.

The preferred commercial specification is a release and expiry framework built around radiochemical purity, chemical purity, sterility, bacterial endotoxins, particulate matter, pH, appearance, and radionuclide identity and activity. The product should not rely on a broad excipient package to compensate for weak control of the chelation process.

What formulation patents protect Indium In-111 DTPA?

The principal commercial value is unlikely to come from a new composition-of-matter patent. The indium-111-DTPA complex is an established diagnostic radiopharmaceutical, and the basic formulation is relatively simple.

Potentially protectable areas include:

• A stabilized aqueous formulation with improved end-of-shelf-life radiochemical purity.
• A low-metal manufacturing process that reduces free indium.
• A ready-to-use formulation with extended regional shipping time.
• A unit-dose presentation that reduces radiopharmacy manipulation.
• A container or closure system that reduces adsorption and extractables.
• A cold-kit format in which DTPA and excipients are supplied for radiolabeling with indium-111 chloride.
• A formulation designed for automated dose dispensing.
• A method of controlling radiolysis without compromising intrathecal tolerability.

A patent directed only to conventional water, sodium chloride, pH adjustment, and DTPA concentrations would face substantial validity and inventive-step pressure. Stronger claims would need comparative stability data, an unexpected radiochemical benefit, a specific container interaction, or a manufacturing advantage.

What is the Orange Book status of Indium In-111 DTPA?

Indium In-111 DTPA is a conventional diagnostic radiopharmaceutical rather than a biologic. Biosimilar competition is therefore irrelevant. The relevant competitive pathways are an abbreviated or full generic drug application, an alternative NDA, hospital radiopharmacy preparation, and substitution by another diagnostic modality.

The commercial protection profile is primarily operational:

• FDA approval and labeling;
• radiopharmaceutical manufacturing compliance;
• radioactive-material licensing;
• validated aseptic processing;
• access to indium-111 supply;
• nuclear pharmacy distribution;
• hospital and imaging-center contracts.

A product-specific formulation patent could provide additional protection, but the base DTPA chemistry is unlikely to support broad exclusivity. Current FDA listing, patent, and exclusivity data should be reviewed in the Orange Book and Drugs@FDA records before a launch or freedom-to-operate decision. FDA identifies radiopharmaceuticals as drug products subject to applicable drug-quality and labeling requirements, while radioactive-material handling also falls under Nuclear Regulatory Commission or Agreement State controls. [1,2]

When does Indium In-111 DTPA lose exclusivity?

Indium In-111 DTPA does not have a biologic exclusivity period. Any remaining regulatory or commercial exclusivity depends on the specific approved product, application, patents, and market status.

For a new entrant, the practical loss of exclusivity risk is less important than substitution risk. A competitor may enter through:

• An approved generic or alternative NDA.
• A radiopharmacy-prepared product where legally permitted.
• A ready-to-label kit.
• A competing technetium-99m product.
• MRI, CT, or another non-radioisotopic diagnostic approach.

The short physical half-life reduces the value of conventional long-term inventory protection. A manufacturer with a product patent could still face rapid commercial erosion if hospitals can replace the product with an established alternative and radiopharmacies can source a comparable product locally.

Are Paragraph IV challenges likely for Indium In-111 DTPA?

Paragraph IV activity is likely to be limited. A challenge would make commercial sense only if an active Orange Book-listed patent materially blocked approval and the market size justified litigation costs.

The most vulnerable claims would be:

• Broad claims to indium-111 complexed with DTPA.
• Conventional aqueous formulations.
• Routine isotonicity or pH ranges.
• Standard vial and single-dose presentations.

More defensible claims could cover a demonstrated stability advantage, a specific radiolysis-control system, an automated preparation process, or a container interaction that improves dose recovery. Even then, the expected market size may discourage a challenger from pursuing extended patent litigation.

What manufacturing and intellectual-property barriers exist?

The principal barriers are manufacturing and distribution barriers rather than basic formulation IP.

Manufacturing barriers

A commercial producer must control:

• Indium-111 radionuclide sourcing.
• Metal contamination during synthesis and filling.
• Aseptic processing.
• Radiochemical purity.
• Radionuclide identity and activity.
• Sterility and endotoxin limits.
• Radiation shielding and worker safety.
• Dose calibration and release timing.
• Short-dated inventory management.
• Regional delivery to nuclear pharmacies.

Indium-111 is commonly produced by cyclotron-based methods, creating dependence on specialized isotope infrastructure. The 67.3-hour half-life provides more distribution time than many short-lived PET isotopes, but it still imposes meaningful shipping and inventory constraints.

Intellectual-property barriers

Potential IP around the base product is likely to be weak unless it includes:

• A new chelation process;
• A validated radiolysis-control system;
• A stable high-concentration formulation;
• A specialized container;
• A kit or automated preparation method;
• A clinically differentiated method of use.

Trade secrets involving low-metal processing, labeling yield, release testing, and dose recovery may be more valuable than broad formulation patents.

What commercial opportunities exist for Indium In-111 DTPA?

The most credible opportunities are operational and service-based.

Regional ready-to-use supply

A manufacturer can compete on delivery reliability, dose scheduling, radiochemical purity at administration, and reduced preparation burden. This model is strongest in regions with established nuclear pharmacies and limited local production.

Unit-dose and hospital contract supply

Single-dose vials or patient-specific syringes can reduce manipulation and waste. Contracts with hospitals and imaging networks may support recurring volume even when total market demand is modest.

Cold-kit development

A kit containing DTPA and optimized excipients for radiolabeling with indium-111 chloride could reduce shipping burden and enable regional preparation. The kit must demonstrate consistent labeling yield, radiochemical purity, sterility, and stability after reconstitution.

The kit strategy introduces a regulatory distinction between a ready-to-use radiopharmaceutical and a kit for radiolabeling. It also shifts some manufacturing and quality responsibilities to the radiopharmacy.

Automated radiopharmacy preparation

A formulation compatible with automated dispensing systems could support centralized production, dose accuracy, and labor reduction. Relevant design parameters include vial geometry, stopper puncture performance, low adsorption, and predictable withdrawal volume.

Contract manufacturing

Contract development and manufacturing organizations can provide isotope handling, aseptic filling, release testing, and regional distribution. This is commercially attractive for small marketing authorization holders that lack dedicated radiopharmaceutical infrastructure.

Lifecycle extensions

Incremental products could include:

• Longer in-use stability after dose preparation;
• Lower residual-volume packaging;
• Improved dose recovery;
• Reduced container adsorption;
• Improved shipping stability;
• A standardized kit presentation;
• A pediatric or low-activity dose configuration, subject to clinical and regulatory support.

How does Indium In-111 DTPA compare with technetium-99m DTPA?

Technetium-99m DTPA is the closest radiolabeled comparator but has different commercial characteristics.

Factor	Indium In-111 DTPA	Technetium-99m DTPA
Half-life	Approximately 67.3 hours	Approximately 6 hours
Distribution	Regional distribution possible	Usually prepared close to the imaging site
Imaging	SPECT or planar imaging	SPECT or planar imaging
Typical role	Specialized CSF and cisternography applications	Broader nuclear medicine use
Supply model	Ready-to-use product or specialized preparation	Generator- or kit-based radiopharmacy model
Cost pressure	Higher specialization and isotope cost	Stronger volume economics
Substitution risk	MRI, CT, and other diagnostics	Broader competitive and clinical use

Indium In-111 DTPA can support longer-distance distribution, but technetium-99m DTPA benefits from broader radiopharmacy familiarity and established kit infrastructure. The commercial positioning should focus on clinical utility, scheduling reliability, and product availability rather than low price alone.

What FDA and regulatory requirements affect commercialization?

FDA requirements include chemistry, manufacturing, and controls data; validated aseptic processing; radiochemical and chemical specifications; stability data; labeling; and controls for radioactive activity and dose calibration. Intrathecal administration raises the standard for excipient selection, particulate control, sterility assurance, endotoxin control, and container-closure validation.

The manufacturer also needs a coordinated regulatory model covering:

• FDA drug approval;
• Current good manufacturing practice;
• Radioactive-material licensing;
• Transportation and packaging rules;
• Radiation-safety procedures;
• Nuclear pharmacy operations;
• Pharmacovigilance and adverse-event reporting.

The FDA label and current prescribing information should control the final excipient composition, route, dose, and handling instructions. [1,3]

What revenue exposure and launch scenarios exist?

Revenue exposure is concentrated in procedure volume, supply reliability, and isotope availability rather than chronic prescription demand.

Launch scenario	Commercial profile	Main risk
Ready-to-use national product	Highest control over formulation and quality	Radioactive inventory and distribution expense
Regional nuclear pharmacy supply	Lower infrastructure burden	Dependence on local contracts
Cold kit	Potentially broader geographic reach	More complex labeling and radiopharmacy preparation
Contract-manufactured product	Lower capital requirement	Margin sharing and supply-chain dependence
Premium stability formulation	Potential pricing advantage	Must demonstrate measurable clinical or operational value

A launch based only on a conventional formulation is likely to compete primarily on availability, price, and service. A differentiated excipient strategy can support premium positioning only if it produces a measurable benefit such as longer usable shelf life, higher dose recovery, lower radiochemical impurity, or reduced preparation waste.

Key Takeaways

• DTPA is a functional chelator and should be optimized as part of the active radiolabeled complex.
• The preferred formulation is simple, aqueous, preservative-free, single-dose, and suitable for intrathecal use.
• Sodium chloride, water for injection, and tightly controlled pH adjustment are the most commercially defensible excipient choices.
• Surfactants, antimicrobial preservatives, and complex buffer systems should generally be avoided unless supported by route-specific and stability data.
• Broad patents on the basic indium-111-DTPA formulation are likely to be vulnerable; process, container, kit, and stability claims offer stronger opportunities.
• Biosimilar risk does not apply. Generic, alternative NDA, hospital preparation, and diagnostic substitution are the relevant competitive threats.
• The strongest commercial opportunities are regional ready-to-use supply, cold kits, automated radiopharmacy preparation, and contract manufacturing.
• The main barriers are isotope supply, aseptic radioactive manufacturing, metal contamination, short-dated inventory, licensing, and nuclear pharmacy distribution.
• Indium In-111 DTPA competes against technetium-99m DTPA and non-radioisotopic diagnostic methods, especially MRI and CT.
• A differentiated formulation must demonstrate a practical benefit in radiochemical purity, stability, dose recovery, logistics, or labor reduction.

FAQs

Is DTPA an excipient or the active ingredient in Indium In-111 DTPA?

DTPA is the chelating ligand that forms the indium-111-DTPA complex. In formulation and regulatory analysis, it is a functional component of the radiolabeled drug substance rather than a passive excipient.

Can preservatives be used in intrathecal Indium In-111 DTPA?

Preservative-free presentation is the preferred strategy for intrathecal administration. A preservative would require a strong route-specific safety justification and supporting regulatory data.

Is a cold kit commercially better than a ready-to-use Indium In-111 DTPA product?

A cold kit can improve geographic reach and reduce transport of radioactive inventory, but it transfers preparation responsibilities to radiopharmacies and requires robust post-labeling stability and quality controls.

Does Indium In-111 DTPA have biosimilar competition?

No. Indium In-111 DTPA is a small-molecule radiopharmaceutical, so the relevant competition is generic or alternative-drug entry, radiopharmacy preparation, and diagnostic substitution.

What is the strongest patent strategy for a new Indium In-111 DTPA product?

The strongest strategy would focus on validated radiochemical stability, low-metal manufacturing, container performance, automated preparation, or an improved kit rather than broad claims to the established indium-111-DTPA complex.

References

1. U.S. Food and Drug Administration. (n.d.). Indium In-111 DTPA injection prescribing information. DailyMed.
2. U.S. Nuclear Regulatory Commission. (n.d.). Medical use of radioactive material and radiopharmaceutical licensing requirements.
3. U.S. Food and Drug Administration. (2016). PET drugs: Current good manufacturing practice; small entity compliance guide.
4. International Atomic Energy Agency. (2019). Cyclotron produced radionuclides: Physical characteristics and production methods. IAEA.